Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity. To address this problem, a novel trivalent PEGylated...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Shiwen, Sun, Dong, Wang, Hong, Wang, Jinliang, Yan, Huijing, Zhao, Xuan, Fawcett, John Paul, Xu, Xin, Cai, Deqi, Gu, Jingkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466002/
https://www.ncbi.nlm.nih.gov/pubmed/37655324
http://dx.doi.org/10.1016/j.apsb.2023.01.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466002/
https://www.ncbi.nlm.nih.gov/pubmed/37655324
http://dx.doi.org/10.1016/j.apsb.2023.01.011

Ejemplares similares